Skip to main
HCAT

HCAT Stock Forecast & Price Target

HCAT Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 11%
Buy 11%
Hold 78%
Sell 0%
Strong Sell 0%

Bulls say

Health Catalyst is a profitable company with strong recurring revenue and a potential acquisition market for its applications, evidenced by the success of its peer company Premier last year. This, combined with a conservative 2x revenue multiple, indicates the potential for Health Catalyst to generate significant proceeds from its applications segment, possibly nearing $100 million.

Bears say

Health Catalyst is facing pressure as their core data infrastructure platform is underperforming, causing a disappointing outlook for revenues and EBITDA. This is intensified by the lack of annual guidance due to ongoing strategic and operational reviews and a recent CEO transition. However, there may be opportunities for the company to create shareholder value through divesting certain attractive app layer assets or potentially selling the entire company. Additionally, monetizing assets such as VitalWare could provide a way out of the current situation and allow the company to focus on growth in the insights and apps layer.

HCAT has been analyzed by 9 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 11% recommend Buy, 78% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Health Catalyst Inc (HCAT) Forecast

Analysts have given HCAT a Hold based on their latest research and market trends.

According to 9 analysts, HCAT has a Hold consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Health Catalyst Inc (HCAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.